Pages that link to "Q50947709"
Jump to navigation
Jump to search
The following pages link to Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia (Q50947709):
Displaying 50 items.
- Treatment of euvolemic hyponatremia in the intensive care unit by urea (Q21194912) (← links)
- Clinical practice guideline on diagnosis and treatment of hyponatraemia (Q22241512) (← links)
- Current and future treatment options in SIADH (Q24652519) (← links)
- Efficacy and Safety of Vasopressin Receptor Antagonists for Euvolemic or Hypervolemic Hyponatremia: A Meta-Analysis (Q26747663) (← links)
- Is chronic hyponatremia a novel risk factor for hip fracture in the elderly? (Q27024448) (← links)
- Novel treatment targets for cerebral edema (Q28254203) (← links)
- Conivaptan for hyponatremia in the neurocritical care unit (Q28300617) (← links)
- Lixivaptan - an evidence-based review of its clinical potential in the treatment of hyponatremia (Q30418165) (← links)
- Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy (Q30432267) (← links)
- Management of hyponatremia (Q33590642) (← links)
- Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit (Q33646385) (← links)
- Oral tolvaptan is safe and effective in chronic hyponatremia (Q33748535) (← links)
- Clinical practice guideline on diagnosis and treatment of hyponatraemia. (Q34406779) (← links)
- Non-peptide arginine-vasopressin antagonists: the vaptans (Q34777664) (← links)
- Syndrome of inappropriate antidiuretic hormone secretion: Revisiting a classical endocrine disorder (Q35244626) (← links)
- Short-term efficacy and safety of vasopressin receptor antagonists for treatment of hyponatremia. (Q35275760) (← links)
- Hyponatremia in the intensive care unit: How to avoid a Zugzwang situation? (Q36265206) (← links)
- Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan (Q36319648) (← links)
- Clinical management of SIADH. (Q36328081) (← links)
- Efficacy of 3% saline vs. conivaptan in achieving hyponatremia treatment goals. (Q36694097) (← links)
- Diagnosis and management of hyponatremia in cancer patients (Q36911286) (← links)
- Vaptans and hyponatremia in critical patients (Q37058365) (← links)
- Hyponatremia in acute heart failure syndromes: a potential therapeutic target (Q37067650) (← links)
- Vasopressin and vasopressin antagonists in heart failure and hyponatremia (Q37258787) (← links)
- Treatment options for hyponatremia in heart failure (Q37262865) (← links)
- Emerging diuretics for the treatment of heart failure (Q37386310) (← links)
- Pharmacologic management of the cardiorenal syndrome in heart failure (Q37503824) (← links)
- Conivaptan: promise of treatment in heart failure (Q37575489) (← links)
- Efficacy of conivaptan and hypertonic (3%) saline in treating hyponatremia due to syndrome of inappropriate antidiuretic hormone in a tertiary Intensive Care Unit (Q37579404) (← links)
- Hyponatremia in neurosurgical patients: clinical guidelines development (Q37615845) (← links)
- Pharmacokinetics of conivaptan use in patients with severe hepatic impairment. (Q37649877) (← links)
- Vasopressin-receptor antagonists (Q37770574) (← links)
- Conivaptan: Evidence supporting its therapeutic use in hyponatremia (Q37778737) (← links)
- Significance of hyponatremia in heart failure (Q37788586) (← links)
- Hyponatremia in Acute Decompensated Heart Failure: Mechanisms, Prognosis, and Treatment Options (Q37810828) (← links)
- Managing hyponatremia in patients with syndrome of inappropriate antidiuretic hormone secretion (Q37818637) (← links)
- Diagnostic approach and management of inpatient hyponatremia (Q37820937) (← links)
- Managing hyponatremia in patients with heart failure (Q37820941) (← links)
- Vaptans for the treatment of hyponatremia (Q37833895) (← links)
- Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). (Q37843827) (← links)
- Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet (Q37859619) (← links)
- Hyponatremia and the Use of Vasopressin Receptor Antagonists In Critically Ill Patients (Q37875586) (← links)
- Use of Intravenous Conivaptan in Neurosurgical Patients With Hyponatremia From Syndrome of Inappropriate Antidiuretic Hormone Secretion (Q37906230) (← links)
- The Therapeutic Use of Vaptans for the Treatment of Dilutional Hyponatremia (Q37911141) (← links)
- The roles of V1a vasopressin receptors in blood pressure homeostasis: a review of studies on V1a receptor knockout mice (Q37950893) (← links)
- Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (Q37959051) (← links)
- Significance of hypo- and hypernatremia in chronic kidney disease (Q37989443) (← links)
- Hyponatremia, Heart Failure, and the Role of Tolvaptan (Q37995861) (← links)
- Pathophysiology, impact, and management of hyponatremia (Q38001416) (← links)
- Therapeutic effect of conivaptan bolus dosing in hyponatremic neurosurgical patients (Q38073203) (← links)